Aunan JR, Cho WC, Søreide K (2017) The biology of aging and cancer: a brief overview of shared and divergent molecular hallmarks. Aging Dis 8(5):628–642. https://doi.org/10.14336/AD.2017.0103

Article  PubMed  PubMed Central  Google Scholar 

Nolen SC, Evans MA, Fischer A, Corrada MM, Kawas CH, Bota DA (2017) Cancer-incidence, prevalence and mortality in the oldest-old. A comprehensive review. Mech Ageing Dev 164:113–126. https://doi.org/10.1016/j.mad.2017.05.002

Article  PubMed  PubMed Central  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

Article  CAS  PubMed  Google Scholar 

Ohno S, Chen Y, Sakamaki H, Matsumaru N, Tsukamoto K (2020) A population-based study of the humanistic burden among cancer patients in Japan. J Med Econ 23(5):429–441. https://doi.org/10.1080/13696998.2019.1707213

Article  PubMed  Google Scholar 

Ohno S, Chen Y, Sakamaki H, Matsumaru N, Tsukamoto K (2020) Factors associated with humanistic burden and indirect cost among patients with cancer in Japan. J Med Econ 23(12):1570–1578. https://doi.org/10.1080/13696998.2020.1839234

Article  PubMed  Google Scholar 

Code of Federal Regulations. §601.41 (1992) https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-601/subpart-E/section-601.41 . Accessed 6 Feb 2025

US Food and Drug Administration (2014) Guidance for industry expedited programs for serious conditions – drugs and biologics. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf. Accessed 6 Feb 2025

Code of Federal Regulations. §314.510 (1992) https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-H/section-314.510. Accessed 29 Apr 2025

Liu ITT, Kesselheim AS, Cliff ERS Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval. JAMA 331(17):1471-1479. https://doi.org/10.1001/jama.2024.2396

Ministry of Health, Labour and Welfare (2006) Revision version of “Guideline for Clinical Evaluation of Anti-Cancer Drugs”

Implementation of a Conditional Early Approval System for Pharmaceutical Products (2022) Pharmaceuticals and Medical Devices Agency. https://www.pmda.go.jp/files/000227089.pdf. Accessed 6 Feb 2025

Hwang TJ, Kesselheim AS, Tibau A, Lee CC, Vokinger KN (2022) Clinical benefit and expedited approval of cancer drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO Oncol Pract 18(9):e1522–e1532. https://doi.org/10.1200/OP.21.00909

Article  PubMed  PubMed Central  Google Scholar 

Poirier AF (2015) Closing the drug lag for new drug submission and review in Japan: an industry perspective. Clin Pharmacol Ther 98(5):486–488. https://doi.org/10.1002/cpt.192

Article  CAS  PubMed  Google Scholar 

Yonemori K, Hirakawa A, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Fujiwara Y (2011) The notorious “drug lag” for oncology drugs in Japan. Investig New Drugs 29(4):706–712. https://doi.org/10.1007/s10637-011-9638-0

Article  Google Scholar 

Ushijima S, Matsumaru N, Tsukamoto K (2021) Evaluation of drug lags in development initiation, new drug application and approval between Japan and the USA and the impact of local versus multi-regional clinical trials. Pharm Med 35(4):253–260. https://doi.org/10.1007/s40290-021-00393-w

Article  Google Scholar 

Maeda H, Hara A, Ofuchi M, Shingai R, Misumi T, Murai Y (2023) Trends in oncology drug lags in Japan from 2001 to 2020: a cross-sectional study. Clin Transl Sci 16(12):2665–2674. https://doi.org/10.1111/cts.13660

Article  PubMed  PubMed Central  Google Scholar 

Nakamura H, Wakutsu N, Murayama S, Suzuki T (2022) An empirical analysis of Japan’s drug development lag behind the United States. J Clin Pharmacol 62(7):847–854. https://doi.org/10.1002/jcph.2023

Article  CAS  PubMed  Google Scholar 

Tachibana Y, Narukawa M (2023) Oncology drug lag in Japan: has it improved over the last decade? Int J Clin Oncol 28(11):1451–1460. https://doi.org/10.1007/s10147-023-02395-x

Article  PubMed  Google Scholar 

Tachibana Y, Yoon J, Narukawa M (2025) Comparison of oncology drug lag in Japan and South Korea based on the interval between the U.S. approval and the local approval. Biol Pharm Bull 48(1):11–16. https://doi.org/10.1248/bpb.b24-00555

Article  CAS  PubMed  Google Scholar 

Health Science Council, Pharmaceutical and Medical Device System Subcommittee (2025) Summary of the revision of the pharmaceuticals and medical devices act and other systems. https://www.mhlw.go.jp/content/11120000/001371285.pdf. Accessed 6 Feb 2025

CDER drug and biologic accelerated approvals based on a surrogate endpoint. https://www.fda.gov/media/151146/download?attachment. Accessed 07 May 2025

U.S FDA drug approvals and databases. https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases. Accessed 07 May 2025

PMDA website for information search of medical drugs. https://www.pmda.go.jp/PmdaSearch/iyakuSearch/. Accessed 07 May 2025

MHLW website strategy of SAKIGAKE. https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/140729-01.html . Accessed 02 May 2025

Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244

Article  CAS  PubMed  Google Scholar 

Shiga K, Shibata T, Miyata T (2025) Evaluation of drug lag and drug loss in Japan: participation in global phase III oncology trials. Int J Clin Oncol. https://doi.org/10.1007/s10147-025-02756-8

Beaver JA, Pazdur R (2021) ‘Dangling’ accelerated approvals in oncology. N Engl J Med 384(18):e68. https://doi.org/10.1056/NEJMp2104846

Article  CAS  PubMed  Google Scholar 

Beaver JA, Howie LJ, Pelosof L, Kim T, Liu J, Goldberg KB, Sridhara R, Blumenthal GM, Farrell AT, Keegan P, Pazdur R, Kluetz PG (2018) A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol 4(6):849–856. https://doi.org/10.1001/jamaoncol.2017.5618

Article  PubMed  Google Scholar 

Tanaka M, Miyazawa H, Terashima R, Ikuma M (2023) Conditional early approval for new drug applications in Japan: current and emerging issues. Clin Transl Sci 16(8):1289–1293. https://doi.org/10.1111/cts.13536

Article  PubMed  PubMed Central  Google Scholar